A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Psoriasis Treated With Ustekinumab and Other Types of Biological and Systemic Non-biological Treatments.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 17 Mar 2017
At a glance
- Drugs Ustekinumab (Primary) ; Antipsoriatics; Tumour necrosis factor inhibitors
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Janssen Biotech
- 10 Feb 2017 Planned number of patients changed from 1000 to 2000.
- 23 Apr 2012 Actual initiation date (Aug 2009) added as reported by ClinicalTrials.gov.
- 23 Apr 2012 Planned number of patients 1000 added as reported by ClinicalTrials.gov..